Oncolytic virotherapy is gaining momentum. 😊☣️🧫🧬👩🏼🔬🔬
Imugene Secures Chinese Patent For Oncolytic Virotherapy CF33 Imugene Limited Leslie Chong https://lnkd.in/g3aip9Xv
VacV Biotherapeutics
Biotechnology Research
Developing oncolytic viruses as therapeutics for cancer
About us
VacV Biotherapeutics is a cancer immunotherapy company developing innovative viral-based therapies for cancers. Launched in 2022 by cancer immunotherapy pioneers Professor Yaohe Wang, Professor Nicholas Lemoine, Dr. Louisa Chard Dunmall and Dr. Peng Liu, VacV employs a unique approach to immunotherapy based on the Vaccinia virus to stimulate a patient’s immune system to fight cancer while simultaneously destroying cancer cells. This approach offers many advantages over existing immunotherapies, including minimized toxicity, higher specificity and efficacy, allowing for efficient systemic delivery of an immunotherapy for the first time.
- Website
-
http://vacvbtx.com/
External link for VacV Biotherapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Privately Held
Locations
-
Primary
Get directions
London, GB
Employees at VacV Biotherapeutics
Updates
-
Oncolytic Vaccinia Virus Showing Efficacy in Combination Therapy 👨🔬
Principal Scientist | Immuno-oncology | Cancer Vaccines and Immunotherapy | Drug Discovery | Project Leader | R&D
Oncolytic Vaccinia Virus Reshapes Extra-Cellular Matrix, Enhancing Chemo-Immunotherapy Effectiveness 🔬 ☣ One major challenge in cancer treatment is the tumour microenvironment. Its extracellular matrix functions as a barrier preventing access of anti-cancer drugs and immune cells from destroying the tumour. To address this, a team of scientists from the Medical School of Nanjing University, Nanjing, Jiangsu, China engineered OVV-Hyal1, an oncolytic vaccinia virus armed with hyaluronidase, to disrupt the tumour microenvironment's extracellular matrix, enhancing drug penetration. In mice, OVV-Hyal1 demonstrated potent antitumour effects alone or combined with chemo drugs, polypeptides, immune checkpoint blockade, or CAR-T cells. It promoted intratumoral drug spread, immune cell infiltration, and CD8+ T cell activation. OVV-Hyal1 shows promise in overcoming barriers in cancer therapy, offering enhanced efficacy in conjunction with existing treatments. If you found this post valuable, give it a like and share it with your network! 😃 #CancerTherapy #TumorMicroenvironment #OVVHyal1 #Immunotherapy #DrugPenetration #ImmunoOncology #CancerResearch #OncolyticVirus #VacciniaVirus Be at the forefront of cancer immunotherapy breakthroughs! 🔬 Subscribe for FREE to my weekly Newsletter for a dose of knowledge and the latest advancements: https://lnkd.in/ec5sV-iP 📧 #ImmunotherapyFrontiers #StayInformed #ImmunotherapyExploration #DontMissOut"
-
-
This week's newsletter delves into the realm of personalized cancer vaccines and the latest breakthroughs in cancer treatment 💉 🔬 👨🔬 #cancerresearch #cancerimmunotherapy #immunooncology #cancervaccine #neoantigens #personalizedmedicine #medicalbreakthrough https://lnkd.in/epkKReCA
Unleashing the Power of Personalized Cancer Vaccines: A Revolution in Immunotherapy
Renato Brito Baleeiro, Ph.D on LinkedIn
-
The power of oncolytic viruses in cancer immunotherapy! 💪
Principal Scientist | Immuno-oncology | Cancer Vaccines and Immunotherapy | Drug Discovery | Project Leader | R&D
Precision Immunotherapy: Engineered Oncolytic Adenovirus Enhances Anti-tumour Response by Rewiring Tumour Microenvironment Researchers have created a new oncolytic adenovirus, RCAd-LTH-shPD-L1, designed to produce anti-VEGF antibodies and shRNA to block PD-L1 expression in tumour cells for targeted cancer immunotherapy. This virus efficiently releases anti-VEGF antibodies, suppresses PD-L1 in cancer cells, and displays specific cytotoxicity towards human cancer cells. In vivo tests demonstrate strong anti-tumour effects in immunodeficient and humanised immune system mouse models, leading to changes in the tumour microenvironment. This focused delivery method proves to be safe and promising for cancer immunotherapy, especially in poorly infiltrating tumours, showcasing the potential of combining virotherapy, anti-angiogenic therapy, and immune checkpoint inhibitors. #ImmunotherapyInnovation #CancerTreatmentBreakthrough #PrecisionMedicine #TumorMicroenvironment #AdenovirusTherapy #OncolyticVirus #ImmunoOncology #ImmuneCheckpointInhibitors
-
-
Innovative Approach to Boosting Cancer Immunotherapies Harvard Medical School researchers discovered a strategy to enhance cancer immunotherapies. Their innovation involves using the protein prosaposin to unveil tumour antigens that were previously hidden from the immune system. By adding prosaposin in a mouse melanoma model, the researchers reactivated the immune response, reducing tumour growth. This promising approach, combined with immune checkpoint inhibitors, showed remarkable results. The team is advancing towards human trials, having filed a patent and developed a targeted delivery system for prosaposin. #CancerResearch #ImmunotherapyInnovation #MedicalBreakthroughs #CancerImmunotherapy #ImmunoOncology
-
-
Towards a Universal Cancer Vaccine: Development of a Tool for the Discovery of Shared Neoantigens In the intricate realm of cancer, where genetic mutations give rise to tumour-specific antigens, scientists from the University of Cincinnati have developed an AI tool called "Splicing Neo Antigen Finder" (SNAF). This bioinformatic marvel navigates the complex genomic landscape, identifying shared splicing neoantigens – the dominant source of tumour-specific peptides. Using that tool, the scientists found that 90% of melanoma patients possess these shared neoantigens, which was subsequently validated in the laboratory. This discovery opens new doors for potential therapies, especially for heterogeneous cancers. SNAF's ability to unveil common elements offers a paradigm shift in personalised immunotherapy, promising a brighter future for effective cancer treatments. #CancerResearch #CancerVaccine #PersonalizedCancerVaccine #ImmunoOncology #NeoAntigen #CancerBreakthrough #UniversalCancerVaccine
-
-
Personalised Cancer Treatment: Patient's Cells act as a Trojan Horse, Guiding Powerful Drugs Directly to Tumours Researchers at The University of Texas at Arlington and UT Southwestern Medical Center are transforming cancer treatment! 🎉 They've developed a clever method to deliver powerful anti-cancer drugs directly into lung cancer cells. 🚀 Using the patient's own T-cells as a trojan horse, this innovative technique ensures precise and targeted drug delivery, reducing side effects. 🎯 The study, published in Bioactive Materials, showed promising results, shrinking tumours effectively. 📈In this innovative method, T-cells are extracted and modified to express a cancer-targeting receptor. The key step involves isolating cell membranes from these modified T-cells, loading them with chemotherapy, and coating tiny drug-delivery granules. Once injected, the coated nanoparticles act like immune cells, guiding chemotherapy precisely to tumour cells, avoiding detection and clearance. This personalised approach holds the potential to revolutionise cancer treatment, offering reduced side effects and improved effectiveness. 🎗️ #CancerResearch #MedicalInnovation #targetedtherapy #Tcells #Nanoparticles #CAR-Tcells #MembraneBasedDrugDelivery #CancerChemotherapy https://lnkd.in/eBntNW3N
Chemotherapy method uses patient's own cells as trojan horse to direct cancer-killing drugs to tumors
medicalxpress.com
-
VacV Biotherapeutics reposted this
Steve Bates OBE FMedSci, CEO, BioIndustry Association (BIA), opens the floor at the #BIACommitteeSummit with a welcome & update about the sector. We now move onto a plenary session celebrating the impact of BIA Advisory Committees past and present 👏 📌 Glyn Edwards, Executive Chairman, VacV Biotherapeutics 📌 Tim Edwards, Chair, STORM Therapeutics Limited 📌 Ruth McKernan, Venture Partner, Dementia Discovery Fund (DDF)
-